223 related articles for article (PubMed ID: 11683962)
1. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.
Lin F; Fukuoka Y; Spicer A; Ohta R; Okada N; Harris CL; Emancipator SN; Medof ME
Immunology; 2001 Oct; 104(2):215-25. PubMed ID: 11683962
[TBL] [Abstract][Full Text] [Related]
2. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
[TBL] [Abstract][Full Text] [Related]
3. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis.
Lin F; Emancipator SN; Salant DJ; Medof ME
Lab Invest; 2002 May; 82(5):563-9. PubMed ID: 12003997
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
[TBL] [Abstract][Full Text] [Related]
5. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
[TBL] [Abstract][Full Text] [Related]
6. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
[TBL] [Abstract][Full Text] [Related]
7. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor.
Miwa T; Okada N; Okada H
Immunogenetics; 2000 Feb; 51(2):129-37. PubMed ID: 10663575
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution of the rat analogue of decay-accelerating factor.
Spiller OB; Hanna SM; Morgan BP
Immunology; 1999 Jul; 97(3):374-84. PubMed ID: 10447757
[TBL] [Abstract][Full Text] [Related]
9. Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.
Li Q; Huang D; Nacion K; Bu H; Lin F
Mol Immunol; 2009 Sep; 46(15):2885-91. PubMed ID: 19660813
[TBL] [Abstract][Full Text] [Related]
10. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.
Lin F; Salant DJ; Meyerson H; Emancipator S; Morgan BP; Medof ME
J Immunol; 2004 Feb; 172(4):2636-42. PubMed ID: 14764738
[TBL] [Abstract][Full Text] [Related]
11. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1.
Cauvi DM; Cauvi G; Pollard KM
J Immunol; 2006 Sep; 177(6):3837-47. PubMed ID: 16951346
[TBL] [Abstract][Full Text] [Related]
12. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
13. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
14. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.
Pavlov V; Raedler H; Yuan S; Leisman S; Kwan WH; Lalli PN; Medof ME; Heeger PS
J Immunol; 2008 Oct; 181(7):4580-9. PubMed ID: 18802060
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Decay Accelerating Factor Mitigates Fibrotic Responses to Lung Injury.
Vittal R; Fisher AJ; Thompson EL; Cipolla EM; Gu H; Mickler EA; Varre A; Agarwal M; Kim KK; Vasko MR; Moore BB; Lama VN
Am J Respir Cell Mol Biol; 2022 Oct; 67(4):459-470. PubMed ID: 35895592
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of decay-accelerating factor isoforms in the digestive tract of guinea pig.
Mizoshita T; Joh T; Oshima T; Yamada T; Ohara H; Nomura T; Okada N; Itoh M
Life Sci; 2002 Jan; 70(8):867-76. PubMed ID: 11853224
[TBL] [Abstract][Full Text] [Related]
17. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice.
Fang C; Miwa T; Shen H; Song WC
J Immunol; 2007 Sep; 179(5):3178-86. PubMed ID: 17709533
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
Qian YM; Haino M; Kelly K; Song WC
Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231
[TBL] [Abstract][Full Text] [Related]
19. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack.
Barata L; Miwa T; Sato S; Kim D; Mohammed I; Song WC
J Immunol; 2013 Mar; 190(6):2886-95. PubMed ID: 23390291
[TBL] [Abstract][Full Text] [Related]
20. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
